EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 48 65756 85980 88360 297--
Enterprise Value (EV)1 48 07356 27180 61659 06458 03056 757
P/E ratio 47,3x70,2x54,4x38,9x35,5x30,7x
Yield ------
Capitalization / Revenue 11,2x13,0x15,5x10,5x9,40x8,43x
EV / Revenue 11,1x12,8x15,4x10,3x9,04x7,93x
EV / EBITDA 34,2x39,4x46,6x29,4x26,2x22,5x
Price to Book 12,0x12,7x13,9x9,79x8,33x7,01x
Nbr of stocks (in thousands) 625 710623 248624 334621 752--
Reference price (USD) 77,891,213097,097,097,0
Announcement Date 01/30/202001/27/202101/26/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 4 3484 3865 2335 7376 4187 153
EBITDA1 1 4061 4291 7292 0112 2122 523
Operating profit (EBIT)1 1 3161 3221 5951 8642 0592 338
Operating Margin 30,3%30,1%30,5%32,5%32,1%32,7%
Pre-Tax Profit (EBT)1 1 1679171 7021 7962 0132 362
Net income1 1 0478231 5031 5731 7282 004
Net margin 24,1%18,8%28,7%27,4%26,9%28,0%
EPS2 1,641,302,382,502,733,16
Dividend per Share2 ------
Announcement Date 01/30/202001/27/202101/26/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 1 3101 3301 3411 4071 4511 534
EBITDA1 431398479500504535
Operating profit (EBIT)1 398365445462468498
Operating Margin 30,4%27,4%33,2%32,8%32,3%32,4%
Pre-Tax Profit (EBT)1 391376436435445465
Net income1 340335374389397422
Net margin 26,0%25,2%27,9%27,6%27,3%27,5%
EPS2 0,540,530,590,620,630,67
Dividend per Share ------
Announcement Date 10/27/202101/26/202204/26/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 5855882671 2342 2673 541
Leverage (Debt / EBITDA) -0,42x-0,41x-0,15x-0,61x-1,03x-1,40x
Free Cash Flow1 9256471 4061 4931 5211 783
ROE (Net Profit / Equities) 32,5%26,9%27,0%25,2%23,5%22,9%
Shareholders' equity1 3 2253 0595 5736 2387 3408 747
ROA (Net Profit / Asset) 20,0%17,1%17,8%17,3%16,4%16,3%
Assets1 5 2274 8148 4269 07610 51912 282
Book Value Per Share2 6,507,199,359,9111,613,8
Cash Flow per Share2 1,851,672,742,683,013,32
Capex1 254407326313343368
Capex / Sales 5,85%9,28%6,23%5,46%5,34%5,15%
Announcement Date 01/30/202001/27/202101/26/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 60 297 483 357
Net sales (USD) 5 232 500 000
Number of employees 15 700
Sales / Employee (USD) 333 280
Free-Float 95,9%
Free-Float capitalization (USD) 57 825 346 642
Avg. Exchange 20 sessions (USD) 287 406 825
Average Daily Capital Traded 0,48%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA